Abstract
Pegfilgrastim has equivalent efficacy to daily G-CSF in enhancing neutrophil recovery after chemotherapy, but conclusive data concerning its use for peripheral blood stem cell (PBSC) mobilization are lacking. From 2003 to 2008 we used high-dose chemotherapy in 64 lymphoma patients. At mobilization chemotherapy (ESHAP) the first 26 patients used unconjugated G-CSF, while the remaining 38 patients received Pegfilgrastim. At the time of harvest 25 patients collected stem cells after the use of G-CSF and 36 in the Peg group. No statistical by significant differences were observed in median peripheral CD34+ cells mobilized (77μL versus 71μL) and in collected PBSC (12.3×106/kg versus 9.4×106/kg p=0.76). In the PEG group all patients collected the target PBSC with a single apheresis with a greater proportion of " optimal" mobilizers (83% versus 64%; p=0.05). In conclusion a single dose of Pegfilgrastim could be a valid alternative to unconjugated G-CSF to mobilize PBSC in lymphoma patients.
| Original language | English |
|---|---|
| Pages (from-to) | 321-326 |
| Number of pages | 6 |
| Journal | Transfusion and Apheresis Science |
| Volume | 43 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Dec 2010 |
Fingerprint
ASJC Scopus subject areas
- Hematology
Cite this
A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy. / Simona, Bassi; Cristina, Rabascio; Luca, Nassi; Sara, Steffanoni; Aleksandra, Babic; Paola, Bertazzoni; Federica, Gigli; Pierluigi, Antoniotti; Laura, Orlando; Simona, Sammassimo; Jessica, Quarna; Mara, Negri; Giovanni, Martinelli.
In: Transfusion and Apheresis Science, Vol. 43, No. 3, 12.2010, p. 321-326.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy
AU - Simona, Bassi
AU - Cristina, Rabascio
AU - Luca, Nassi
AU - Sara, Steffanoni
AU - Aleksandra, Babic
AU - Paola, Bertazzoni
AU - Federica, Gigli
AU - Pierluigi, Antoniotti
AU - Laura, Orlando
AU - Simona, Sammassimo
AU - Jessica, Quarna
AU - Mara, Negri
AU - Giovanni, Martinelli
PY - 2010/12
Y1 - 2010/12
N2 - Pegfilgrastim has equivalent efficacy to daily G-CSF in enhancing neutrophil recovery after chemotherapy, but conclusive data concerning its use for peripheral blood stem cell (PBSC) mobilization are lacking. From 2003 to 2008 we used high-dose chemotherapy in 64 lymphoma patients. At mobilization chemotherapy (ESHAP) the first 26 patients used unconjugated G-CSF, while the remaining 38 patients received Pegfilgrastim. At the time of harvest 25 patients collected stem cells after the use of G-CSF and 36 in the Peg group. No statistical by significant differences were observed in median peripheral CD34+ cells mobilized (77μL versus 71μL) and in collected PBSC (12.3×106/kg versus 9.4×106/kg p=0.76). In the PEG group all patients collected the target PBSC with a single apheresis with a greater proportion of " optimal" mobilizers (83% versus 64%; p=0.05). In conclusion a single dose of Pegfilgrastim could be a valid alternative to unconjugated G-CSF to mobilize PBSC in lymphoma patients.
AB - Pegfilgrastim has equivalent efficacy to daily G-CSF in enhancing neutrophil recovery after chemotherapy, but conclusive data concerning its use for peripheral blood stem cell (PBSC) mobilization are lacking. From 2003 to 2008 we used high-dose chemotherapy in 64 lymphoma patients. At mobilization chemotherapy (ESHAP) the first 26 patients used unconjugated G-CSF, while the remaining 38 patients received Pegfilgrastim. At the time of harvest 25 patients collected stem cells after the use of G-CSF and 36 in the Peg group. No statistical by significant differences were observed in median peripheral CD34+ cells mobilized (77μL versus 71μL) and in collected PBSC (12.3×106/kg versus 9.4×106/kg p=0.76). In the PEG group all patients collected the target PBSC with a single apheresis with a greater proportion of " optimal" mobilizers (83% versus 64%; p=0.05). In conclusion a single dose of Pegfilgrastim could be a valid alternative to unconjugated G-CSF to mobilize PBSC in lymphoma patients.
UR - http://www.scopus.com/inward/record.url?scp=78649460876&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649460876&partnerID=8YFLogxK
U2 - 10.1016/j.transci.2010.10.001
DO - 10.1016/j.transci.2010.10.001
M3 - Article
C2 - 21036667
AN - SCOPUS:78649460876
VL - 43
SP - 321
EP - 326
JO - Transfusion and Apheresis Science
JF - Transfusion and Apheresis Science
SN - 1473-0502
IS - 3
ER -